Previous Article | Next Article ![]()
Journal of Bacteriology, September 2004, p. 6265-6276, Vol. 186, No. 18
0021-9193/04/$08.00+0 DOI: 10.1128/JB.186.18.6265-6276.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Seattle Biomedical Research Institute, and Departments of Pathobiology and Microbiology, University of Washington, Seattle, Washington
Received 30 January 2004/ Accepted 9 June 2004
|
|
|---|
|
|
|---|
Multiple mechanisms exist to regulate prfA expression and protein activity. Three promoters contribute to the transcriptional regulation of prfA. The promoters prfAp1 and prfAp2 are located immediately upstream of the prfA coding region and are important for providing the initial levels of PrfA protein required for the activation of gene products essential for bacterial escape from host cell vacuoles (12, 13). These promoters are functionally redundant in vivo and appear to contribute to both positive and negative regulation of prfA expression (12, 13, 19). The third promoter contributing to regulation of prfA is located upstream of the plcA gene and increases prfA expression via the generation of a bicistronic plcA-prfA transcript; this promoter is PrfA dependent and represents a positive feedback loop for prfA expression (5, 13). The 5' untranslated region of prfA mRNA has recently been shown to function as a thermosensor that regulates the translation of prfA mRNA in response to changes in temperature (22).
In addition to the regulation of prfA expression and mRNA translation, the activation state of PrfA appears to be regulated either through the binding of a cofactor or through some mode of posttranslational modification. The PrfA protein is a member of the Crp/Fnr family of transcriptional activators (25, 27, 41) and has significant structural and functional homology to the Escherichia coli cyclic AMP (cAMP) receptor protein (Crp) (17, 39, 41). Crp requires the binding of the cofactor cAMP for full activity, and cAMP-independent, constitutively active Crp* mutants have been described (14). A PrfA mutant analogous to Crp* has been identified in L. monocytogenes (37); a glycine-to-serine substitution at position 145 in PrfA resulted in constitutively high expression of all PrfA-regulated genes (37). The phenotype of the PrfA G145S mutant suggests that PrfA, like Crp, requires cofactor binding or modification for full activity (37). Two additional mutations in PrfA leading to activation of the protein have recently been identified (PrfA E77K and PrfA G155S); both were found to result in increased levels of PrfA-dependent gene expression, but strains containing the mutant alleles were phenotypically distinct, suggesting that the mutations altered different aspects of PrfA function (43).
In this study, we describe a fourth PrfA mutation (PrfA L140F) that results in the constitutive activation of PrfA but is also functionally distinct from the three previously described constitutive PrfA mutations.
|
|
|---|
was used as a host strain for recombinant plasmids. E. coli strain SM10 (44) was used as the donor strain for conjugation of pPL2 plasmid constructs. L. monocytogenes 10403S (serotype 1/2) is resistant to streptomycin and has a 50% lethal dose for mice of 2 x 104 CFU/ml (13). L. monocytogenes wild-type (WT) strain 10403S containing a chromosomal actA-gus-plcB transcriptional fusion (NF-L476) and NF-L758, a derivative of NF-L476 containing an erythromycin resistance gene (erm) inserted between orfZ and orfB downstream of the PrfA regulon, have been described (43). A 10403S L. monocytogenes strain containing a 339-bp in-frame deletion in prfA was generously provided by Hao Shen (University of Pennsylvania) and Jeff Miller (UCLA); this strain was transduced with a phage U153 lysate (20) obtained from NF-L758, and the resulting erythromycin-resistant transductant was designated NF-L1003. NF-L1003 therefore contains an in-frame deletion of prfA with a downstream copy of erm located between orfZ and orfB in the presence of a chromosomal actA-gus transcriptional fusion. L. monocytogenes strain NF-L879 was isolated as a mutant with high in vitro actA-gus expression following chemical mutagenesis of NF-L476 with ethylene methylsulfonate (EMS) (43). The integration vector pPL2 has been described (28) and was used for the construction of the recombinant pPL2prfA constructs listed in Table 1 (described below). L. monocytogenes and E. coli were grown in brain heart infusion (BHI) broth (Difco Laboratories, Detroit, Mich.) and Luria broth (LB) (Invitrogen Corp., Grand Island, N.Y.), respectively. For selection of pPL2 or its recombinant plasmids, chloramphenicol at 25 µg/ml was used for E. coli; chloramphenicol at 7.5 µg/ml was used for L. monocytogenes, and streptomycin at 200 µg/ml was used to select for L. monocytogenes following conjugation. For solid media, 2.5% (wt/vol) agar was included. |
View this table: [in a new window] |
TABLE 1. Bacterial strains used in this study
|
U153 bacteriophage-mediated transduction. High-titer U153 lysates (50 to 200 µl) prepared from strain NF-L758 (NF-L476 with an erm insertion downstream of the PrfA regulon) were mixed with 200 µl of mid-exponential-phase L. monocytogenes mutant strain NF-L879 (grown at 30°C with shaking) in the presence of 10 mM MgSO4 and 10 mM CaCl2, and the mixture was incubated at RT for 1 h with occasional gentle mixing. An aliquot of 3 ml of warm BHISA (BHI plus 0.75% [wt/vol] agar-10 mM sodium citrate, pH 7.5) containing 50 µg of 5-bromo-4-chloro-3-indolyl-ß-D-glucuronide salt (XG; Inalco)/ml was added with gentle mixing to the bacteriophage-L. monocytogenes suspension, erythromycin at 1.3 µg/ml was included to induce erm expression, and the mixture was immediately poured onto BHI plates containing 10 mM sodium citrate (pH 7.5) and 50 µg of XG/ml. After incubation at 37°C for 2 h, another layer of BHISA containing 50 µg of XG/ml and 13 µg of erythromycin/ml was poured onto the plates, which were again incubated at 37°C. Bacterial transductants were usually visible within 1 to 2 days, and Ermr transductants were scored for blue or white colony color. Mutants containing mutations closely linked to the erm gene produced white transductants on indicator plates at a frequency that correlated with the distance of the mutation from the erm marker [distance = (1 the cube root of the transduction frequency) x phage size (40.8 kb for U153)] (20). Transductants isolated after phage infection of mutant NF-L879 were either dark blue or white. The dark-blue ones retained the mutation that conferred a high level of in vitro actA-gus expression, whereas the white colonies contained the WT copy of prfA from NF-L758.
Construction of pPL2 recombinant plasmids.
Genomic DNA was isolated from the L. monocytogenes WT strain NF-L476 and the EMS mutant strain NF-L879 for splicing by overlap extension PCR (21) to clone the WT or mutant prfA genes with the prfA and plcA promoters and their PrfA-binding palindromes into the integrative vector pPL2. The primers 5'SacI-pPlcA (5'-GGGAATTCGGTATCAAATAAAACG-3'; the added SacI site is underlined) and 3'SalI prfA tx term (5'-AATCGCTTTCTTTACTGCAGGA-3'; the added SalI site is underlined) (sequences of both primers were provided by D. Higgins, Harvard Medical School, Boston, Mass.) were used as the external primer pair for splicing by overlap extension PCR with the internal primer pairs delplcAR (5'-TACTTTGTTGTTTAATGCTGCATTAAAATAAATTGG-3') and delplcAF (5'-CCAATTTATTTTAATGCAGCATTAAACAACAAAGTA-3'). The internal primers generated a 453-bp in-frame deletion in plcA. An
500-bp product was obtained from PCR with 5'SacI-pPlcA and delplcAR, and a 1.2-kb fragment was amplified with delplcAF and 3'SalI prfA tx term. The two overlapping products formed were purified with a QIAquick gel extraction kit (Qiagen Inc., Valencia, Calif.) and subjected to a second PCR containing only the two external primers. The final product (
1.7 kb) was gel purified, digested with SacI and SalI, and ligated to pPL2 cut with the same enzymes for transformation into E. coli DH5
. After the inserted fragments were checked by sequencing, each of the recombinant plasmids was electroporated into E. coli SM10 for conjugation into recipient L. monocytogenes strains.
Conjugation and plasmid integration.
Conjugation of the pPL2 recombinant plasmids from E. coli SM10 into recipient strains was performed as previously described (28) with slight modifications. Briefly, the bacterial strains were grown at 30°C with shaking to mid-log phase (optical density at 600 nm [OD600],
0.6). E. coli donor strains were grown in LB containing 25 µg of chloramphenicol/ml, and L. monocytogenes recipient strains were grown in BHI. The donor culture (250 µl) was mixed with 150 µl of recipient culture, put onto a 0.45-µm-pore-size HA-type filter (Millipore, Billerica, Mass.) on a BHI plate without antibiotics, and incubated at 30°C for 2 h. The bacterial cells were then resuspended in 2 ml of BHI, and aliquots (50 to 200 µl) were mixed with 3 ml of LB top agar and overlaid onto BHI plates with 7.5 µg of chloramphenicol/ml and 200 µg of streptomycin/ml. The plates were then incubated at 30°C overnight and shifted to 37°C for 2 to 3 days. Individual colonies were screened by PCR. The colonies were picked with sterile toothpicks, streaked onto a fresh selection plate, and then boiled at 100°C for 10 min in 75 µl of sterile water. PCR was performed with 5 µl of the boiled bacterial suspension. The primer pair NC16 (5'-GTCAAAACATACGCTCTTATC-3') and PL95 (5'-ACATAATCAGTCCAAAGTAGATGC-3') amplified a 499-bp product in strains that are lysogenic or contain the integration vector at tRNAArg-attBB' (28). The primer pairs 5'SacI-pPlcA and 3'SalI prfA tx term amplified a single 2.1-kb product from NF-L476 or when the vector alone (pPL2) was integrated into the chromosome; a single 1.8-kb fragment was amplified from NF-L1003 (
prfA) and its pPL2 integrant. An additional band at
1.7-kb was obtained if a pPL2 recombinant plasmid carrying a prfA allele was integrated into the chromosome. Potential mutant insertion strains were confirmed by PCR using isolated genomic DNA.
Determination of hemolytic activity. Overnight cultures of L. monocytogenes grown without shaking in BHI at 37°C were diluted 1:10 in fresh BHI broth and grown with shaking at 37°C. The culture supernatants were assayed for hemolytic activity with sheep erythrocytes as previously described (4). Hemolytic activity was determined as the reciprocal of the supernatant dilution at which 50% lysis of erythrocytes was observed and then normalized to the OD595 of the bacterial cultures.
Measurement of GUS activity. Overnight cultures of L. monocytogenes grown without shaking in BHI at 37°C were diluted 1:20 into fresh BHI and grown with shaking at 37°C. Chloramphenicol at 7.5 µg/ml was included in the medium for L. monocytogenes strains integrated with the pPL2 vector or a pPL2 recombinant plasmid. At various time points, the OD595 was determined for each culture by using a spectrophotometer (UV-1201 UV-VIS spectrophotometer; Shimadzu Scientific Instruments, Inc., Columbia, Md.). Bacterial pellets were harvested from 1-ml culture suspensions by centrifugation, washed once with ABT buffer (1 M potassium phosphate [pH 7.0], 0.1 M NaCl, 1% Triton), and resuspended in 100 µl or 1 ml of the same buffer. ß-Glucuronidase (GUS) activity was measured as described by Youngman (51) with the substitution of 4-methylumbelliferyl-ß-D-glucuronide (Sigma, St. Louis, Mo.) in place of 4-methylumbelliferyl-ß-D-galactoside.
Motility assays.
Swimming motility was evaluated on semisolid (0.3% [wt/vol] agar) BHI medium treated with 0.2% [wt/vol] activated charcoal as previously described (43). The plates were inoculated with 2 µl of mid-log-phase (OD600,
0.7) bacterial cultures grown in BHI at 37°C; chloramphenicol at 7.5 µg/ml was included in the media for strains with the pPL2 vector or a pPL2 recombinant plasmid integrated into the chromosome. The plates were incubated overnight at 37°C. Motility was quantified as the diameter of the swimming colony minus the diameter of a nonmotile
flaA L. monocytogenes deletion mutant (43). Results were obtained from duplicate samples of two independent experiments for each strain.
Plaque formation in murine L2 fibroblasts.
Plaque assays were performed with murine L2 fibroblasts as described previously (45), with a multiplicity of infection of
1:3. Plaque size was measured using a comparator (Finescale, Orange, Calif.). Chloramphenicol at 5 µg/ml was included in the tissue culture media for L2 cells infected by L. monocytogenes strains integrated with the pPL2 vector or a pPL2 recombinant plasmid. The average diameter of 10 plaques from at least three independent experiments was determined for each strain.
PlcB activity assay. PlcB activities were assayed by streaking bacterial colonies onto BHI medium overlaid with molten agar containing activated-charcoal-treated (0.2% [wt/vol]) BHI and a 5% ([vol/vol]) concentration of a 1:1 egg yolk-phosphate-buffered saline (PBS) solution. The plates were then incubated at 37°C or room temperature for 1 to 2 days.
PrfA monoclonal antibodies. Monoclonal antibody MAB-prfA55 derived against recombinant PrfA protein containing an N-terminal six-residue histidine tag was generated by the Hope Heart Institute (Seattle, Wash.).
SDS-PAGE and Western immunoblotting.
To isolate cell lysates, overnight cultures of L. monocytogenes strains were diluted 1:20 in 30 ml of fresh BHI broth and grown to an OD595 of
0.7 (chloramphenicol at 7.5 µg/ml was included in the media for strains with the pPL2 vector or a pPL2 recombinant plasmid integrated into the chromosome). Each culture was centrifuged at
5,000 x g for 10 min, washed in 1x PBS (Invitrogen, Grand Island, N.Y.), and centrifuged again. Each pellet was resuspended in 400 µl of lysis buffer (50 mM Tris-HCl, pH 7.5, 1 mM dithiothreitol, 0.1% [vol/vol] Triton X-100). Bacterial suspensions were mixed with 200 mg of glass beads (Sigma) and disrupted using a Mini-Beadbeater (Biospec Products, Barttesville, Okla.) at maximum speed for 20 s. Samples were kept on ice and then centrifuged at top speed in a microcentrifuge for 1 min to recover the supernatants. Protein concentrations were determined using the DC Protein Assay kit (Bio-Rad Laboratories, Hercules, Calif.) following instructions provided by the manufacturer. Equivalent amounts of total protein from each culture lysate were mixed with 4x sample buffer (0.25 mM Tris-HCl, pH 6.8, 8% [wt/vol] sodium dodecyl sulfate [SDS], 40% [vol/vol] glycerol, 4% [vol/vol] 2-mercaptoethanol, 0.04% bromophenol blue). Samples were heated to 100°C for 5 min prior to SDS- polyacrylamide gel electrophoresis (SDS-PAGE) on 15% polyacrylamide gels. The proteins were transferred to nitrocellulose membranes at 100 V for 1.5 h. Immunobloting for PrfA or PrfA derivatives was performed at RT. The membranes were briefly washed with 1x PBS, blocked with 5% (wt/vol) nonfat dry milk in 1x PBS for 1 h, and then incubated overnight with a 1:100 dilution of the monoclonal antibody MAB-prfA55 in 1x PBS with 5% (wt/vol) nonfat dry milk and 0.05% (vol/vol) Tween 20. After three 10-min washes in 1x PBS, the membranes were incubated with a 1:2,000 dilution of an alkaline phosphatase-conjugated goat anti-mouse antibody (Sigma, St. Louis, Mo.) for 30 min. Following three 10-min PBS washes and equilibration of the membranes for 5 min in detection buffer (100 mM Tris-HCl, 100 mM NaCl, 50 mM MgCl2, pH 9.5), PrfA proteins were detected by using Sigma Fast 5-bromo-4-chloro-3-indolyl phosphate-nitroblue tetrazolium tablets, a colorimetric alkaline phosphatase substrate. For quantitative comparison of PrfA protein levels visualized by Western analysis, serial dilutions of protein extracts were compared to determine the relative amounts of PrfA produced by different strains.
Intracellular growth in macrophage-like J774 cells.
To examine intracellular growth, cell monolayers were grown on circular coverslips (12-mm diameter) in tissue culture dishes. Bacterial cultures were grown overnight without shaking in BHI at 37°C; chloramphenicol at 7.5 µg/ml was included in the media for strains with the pPL2 vector or a pPL2 recombinant plasmid integrated into the chromosome. The cultures were washed with PBS and then used to infect J774 cells at a multiplicity of infection of
1:20. After infection for 30 min, the monolayers were washed three times with 37°C PBS prior to the addition of 5 ml of 37°C medium, and gentamicin was added to a final concentration of 10 µg/ml at 1 h postinfection to kill any remaining extracellular bacteria. At various time points, the coverslips were removed to determine the number of intracellular bacteria. The cell monolayers on each coverslip were lysed by vortexing them for 10 s in 5 ml of sterile water, and dilutions of the cell lysate were plated on LB plates. Bacterial CFU were determined for each strain in triplicate after overnight incubation at 37°C on LB plates.
|
|
|---|
To determine whether the mutation in NF-L879 was associated with a gene located within or near the prfA locus, the L. monocytogenes-transducing bacteriophage U153 (20) was used to transduce an erythromycin resistance (erm) gene marker linked to the PrfA regulon from strain NF-L758 to the NF-L879 mutant strain. NF-L758 is a derivative of the WT strain NF-L476 (actA gus), which contains a copy of erm inserted downstream of orfXYZ at the 3' end of the PrfA regulon. If the mutation in NF-L879 was closely linked to the PrfA regulon, then transduction of NF-L879 with a phage lysate derived from NF-L758 would result in a population of white transductants with WT levels of actA-gus expression on XG medium, as well as a population of dark-blue transductants that retained the NF-L879 mutation. The frequency of white versus blue transductants would reflect how closely linked the NF-L879 mutation was to the erm marker. If the mutation in NF-L879 was not linked to the PrfA regulon, then transduction of NF-L879 with the NF-L758-derived phage lysate would result in only dark-blue transductants. Transduction of NF-L879 resulted in the isolation of white colonies on XG medium at a frequency of 47% (31 white colonies identified from a total of 66 transductants), indicating that the mutation in NF-L879 conferring high-level in vitro actA expression was closely linked (within
9 kb) to the PrfA regulon. DNA sequence analysis of NF-L879 prfA revealed the presence of a CTT-to-TTT mutation within the prfA coding region, which would result in the replacement of a leucine with a phenylalanine at amino acid 140 of the protein sequence (PrfA L140F) (Fig. 1). This mutation maps near the site of another prfA mutation that has been described (37), PrfA G145S (or PrfA*), which is believed to lock the protein into a constitutively activated state (37, 49). No other mutations were found within the 9-kb region encompassing the prfA regulon of NF-L879.
|
View larger version (7K): [in a new window] |
FIG. 1. Locations of PrfA mutations with respect to predicted protein secondary-structure motifs and functional regions. The previously described PrfA* mutation (G145S) is included for comparison (37). AR, activation region that may form contacts with RNA polymerase; Leu-zip, leucine zipper-like motif. Depictions of structural motifs and functional regions are adapted from Goebel et al. (17).
|
![]() View larger version (72K): [in a new window] |
FIG. 2. Overnight cultures of L. monocytogenes strains grown in BHI broth at 37°C without shaking. The strain numbers and relevant genotypes are shown underneath the respective culture tubes. 476, NF-L476 (WT); 879, NF-L879 (EMS L140F mutant); 1041, NF-L1041 ( prfA + WTi); 1011, NF-L1011 ( prfA + L140Fi); 1067, NF-L1067 (L140F + L140Fi); 1006, NF-L1006 (WT + pPL2i); 1008, NF-L1008 (WT + L140Fi).
|
prfA + L140Fi) settled to the bottoms of tubes in a manner identical to that of the original EMS mutant strain, NF-L879 (Fig. 2). In addition, in contrast to NF-L1041 (
prfA + WTi) or NF-L1042 (
prfA + L147Pi), the NF-L1011 (
prfA + L140Fi) integrant was found to be unstable in the absence of drug selection when grown in BHI broth culture (data not shown), suggesting that the presence of the L140Fi allele may adversely affect some aspect of L. monocytogenes growth.
Analysis of PrfA protein levels in
prfA strains containing integrated copies of WT or mutant prfA.
To compare the levels of PrfA present in prfA integrant strains, total cell extracts derived from broth cultures grown to similar mid-log-phase densities were examined by Western analysis using a mouse monoclonal antibody directed against PrfA. No PrfA was detected in the
prfA parent strain NF-L1003 or in the vector control integrant NF-L1009 (
prfA + pPL2i) (Fig. 3A). The EMS mutant NF-L879 produced increased levels of PrfA protein in comparison to the WT strain NF-L476 (Fig. 3A). Similarly, larger amounts of PrfA protein were detected in the integrant strain NF-L1011 (
prfA + L140Fi) than in the control strain NF-L1041 (
prfA + WTi) (Fig. 3A). Interestingly, no PrfA was detected from the PrfA L147P integrant NF-L1042 (Fig. 3A), even when a rabbit polyclonal antibody against PrfA was used for detection (data not shown). The PrfA L147P mutation therefore appeared to result in an unstable, rapidly degraded form of the protein. For quantitative comparison of PrfA protein levels, serial dilutions of protein extracts were compared (Fig. 3B and C). The EMS mutant NF-L879 produced about two to four times more PrfA protein than the WT strain NF-L476 (Fig. 3B), and the integrant strain NF-L1011 (
prfA + L140Fi) produced at least four times more PrfA protein than the control strain NF-L1041 (
prfA + WTi) (Fig. 3C). These results demonstrated that the introduction of the integrated prfA mutant and WT alleles into L. monocytogenes
prfA strains resulted in levels of PrfA protein that were comparable to WT and mutant protein levels produced by NF-L476 and NF-L879 strains.
![]() View larger version (21K): [in a new window] |
FIG. 3. Western analysis of PrfA protein levels produced by the various L. monocytogenes strains. Soluble bacterial whole-cell lysates were prepared from mid-log-phase cultures. The strain numbers and relevant genotypes are shown above the lanes. PrfA was detected by using a monoclonal antibody against PrfA and an alkaline phosphatase-conjugated goat anti-mouse secondary antibody. (A) PrfA protein levels from L. monocytogenes integrant strains in the NF-L1003 ( prfA) background. Equal amounts of total protein (23 µg) solubilized in SDS-PAGE sample buffer were loaded for each sample. (B) Quantitative comparison of PrfA protein levels from WT strain NF-L476 (476) and original EMS mutant strain NF-L879 (879), with the amount of total proteins loaded in each lane indicated. (C) Quantitative comparison of PrfA protein levels from integrant strains NF-L1041 ( prfA + WTi) (1041) and NF-L1011 ( prfA + L140Fi) (1011), with the amount of total proteins loaded in each lane indicated.
|
Relative amounts of secreted LLO were determined by measuring bacterial supernatants derived from mid-log-phase cultures for hemolytic activity against sheep red blood cells. Supernatants derived from the
prfA strain NF-L1003, the vector control integrant NF-L1009 (
prfA + pPL2i), and the PrfA L147P integrant strain NF-L1042 (
prfA + L147Pi) exhibited very little hemolytic activity (Table 2). The EMS mutant strain NF-L879 produced significantly larger amounts of LLO activity than the WT strain NF-L476 (Table 2), indicating that the PrfA L140F mutation is capable of elevating the expression of PrfA-dependent gene products distinct from actA. The integrated WTi allele in NF-L1041 (
prfA + WTi) complemented the prfA deletion in the NF-L1003 background, and similarly, the integrated L140Fi allele conferred levels of hemolytic activity on NF-L1011 (
prfA + L140Fi) that were comparable to those observed for NF-L879 (Table 2).
|
View this table: [in a new window] |
TABLE 2. Phenotypic analysis of L. monocytogenes strains with prfA mutations
|
prfA) grown in BHI alone (Fig. 4A). The
prfA control strains NF-L1003 and NF-L1009 (
prfA + pPL2i) had almost undetectable levels of GUS activity, and the same was observed for the integrant NF-L1042 (
prfA + L147Pi) (Fig. 4B); all of these strains did not produce detectable PrfA protein as observed by Western analysis (Fig. 3A). The integration of a WTi copy into the prfA deletion strain NF-L1003 completely restored actA expression levels in NF-L1041 (
prfA + WTi) to those observed for the WT strain NF-L476 (Fig. 4B). actA expression of the original EMS mutant NF-L879 was observed to peak during exponential growth, and levels of expression were up to 37-fold higher than the expression levels observed for strains containing a single copy of the WT prfA allele (NF-L476 and NF-L1041) (Fig. 4C). The actA expression profile of integrant NF-L1011 (
prfA + L140Fi) was very similar to that of NF-L879 (Fig. 4C), indicating that the L140F mutation in PrfA was responsible for the high in vitro actA induction in the original EMS mutant. NF-L1011 (
prfA + L140Fi) produced increased levels of PrfA protein in comparison to the original NF-L879 mutant strain (Fig. 3A); the similar levels of actA expression observed for NF-L879 and NF-L1011, therefore, suggest that the mutant PrfA L140F reached a level of PrfA saturation beyond which there was no further increase in the induction of actA expression despite increased production of PrfA.
![]() View larger version (17K): [in a new window] |
FIG. 4. actA expression of PrfA mutant strains and corresponding control strains during growth in broth culture. Units of GUS activity were determined at the indicated time intervals as described in Materials and Methods and were normalized for bacterial culture OD595 (51), using 4-methylumbilliferyl-ß-D-glucuronide as the substrate. The data shown are from duplicate samples and are representative of at least three independent experiments, expressed as average ± standard error. (A) Growth of WT and PrfA mutant strains in BHI broth at 37°C as measured by OD595 of cultures. (B) actA expression from strains NF-L476 (WT), NF-L1003 ( prfA), NF-L1009 ( prfA + pPL2i), NF-L1041 ( prfA + WTi), and NF-L1042 ( prfA + L147Pi). (C) actA expression from strains NF-L476 (WT), NF-L879 (EMS L140F), and NF-L1011 ( prfA + L140Fi).
|
prfA control strains NF-L1003 and NF-L1009 (
prfA + pPL2i) or for the integrant NF-L1042 (
prfA + L147Pi) (Fig. 5). No PlcB activity was observed for WT strain NF-L476 and the integrant NF-L1041 (
prfA + WTi) (Fig. 5). In contrast, NF-L1011 (
prfA + L140Fi) exhibited increased levels of PlcB activity similar to that observed for the original EMS mutant NF-L879 (Fig. 5), even in media not treated with activated charcoal (treatment of BHI broth with activated charcoal has been reported to induce the expression of plcB [38]) (data not shown).
![]() View larger version (128K): [in a new window] |
FIG. 5. PlcB (lecithinase) phenotypes of L. monocytogenes mutants and corresponding control strains on BHI medium overlaid with molten agar containing activated-charcoal-treated (0.2% [wt/vol]) BHI and 5% (vol/vol) 1:1 egg yolk-PBS solution. The plates were incubated at 37°C overnight. 476, NF-L476 (WT); 879, NF-L879 (EMS L140F mutant); 1003, NF-L1003 ( prfA); 1006, NF-L1006 (WT + pPL2i); 1039, NF-L1039 (WT + WTi); 1040, NF-L1040 (WT + L147Pi); 1008, NF-L1008 (WT + L140Fi); 1009, NF-L1009 ( prfA + pPL2i); 1041, NF-L1041 ( prfA + WTi); 1042, NF-L1042 ( prfA + L147Pi); 1011, NF-L1011 ( prfA + L140Fi); 1067, NF-L1067 (L140F + L140Fi).
|
The PrfA L140F mutation is phenotypically dominant to WT PrfA.
The PrfA protein is thought to be active as a multimer based on its similarity to E. coli Crp and on the recently solved PrfA crystal structure (27, 49; http://www.rcsb.org/pdb/). It seemed possible, therefore, that strains producing both the PrfA WT and PrfA L140F proteins might exhibit altered patterns of PrfA-dependent gene expression as a result of PrfA heterodimer formation. The PrfA L140F and PrfA L147P mutations, with the two prfA promoters and the plcA promoter, were therefore introduced into the chromosome of WT strain NF-L476 to examine the potential effects on PrfA-dependent gene expression. prfA merodiploid integrants NF-L1008 (WT + L140Fi) and NF-L1040 (WT + L147Pi) were generated, along with strain NF-L1006 with an integrated vector alone (WT + pPL2i) and a WTi merodiploid strain, NF-L1039 (WT + WTi), as controls. All strains exhibited apparently normal growth characteristics in broth cultures (data not shown). Similar to the EMS mutant NF-L879 and the NF-L1011 (
prfA + L140Fi) integrant, unshaken overnight cultures of NF-L1008 (WT + L140Fi) were observed to settle to the bottoms of culture tubes (Fig. 1).
Western analysis of PrfA protein levels in the vector control integrant NF-L1006 (WT + pPL2i) and the merodiploid NF-L1040 (WT + L147Pi) demonstrated levels of PrfA protein comparable to those of the WT strain NF-L476 (Fig. 6A). This result suggested that mutant PrfA L147P protein was not produced in NF-L1040 (WT + L147Pi) and that the presence of the mutant allele did not affect the expression or stability of WT PrfA. Increased amounts of PrfA protein were detected in extracts derived from NF-L1008 (WT + L140Fi) (Fig. 6A), with protein levels at least fourfold higher than in the vector control integrant NF-L1006 (WT + pPL2i) (Fig. 6B). Two copies of the WTi allele in NF-L1039 (WT + WTi) also led to a >4-fold increase in PrfA synthesis (Fig. 6A and C).
![]() View larger version (21K): [in a new window] |
FIG. 6. Western analysis of PrfA protein levels produced by the various L. monocytogenes strains. Soluble bacterial whole-cell lysates were prepared from mid-log-phase cultures. The strain numbers and relevant genotypes are shown above the lanes. PrfA was detected by using a monoclonal antibody against PrfA and an alkaline phosphatase-conjugated goat anti-mouse secondary antibody. (A) PrfA protein levels from L. monocytogenes integrant strains in the WT strain NF-L476 background. Equal amounts of total protein (23 µg) solubilized in SDS-PAGE sample buffer were loaded for each sample. (B) Quantitative comparison of PrfA protein levels from integrant strains NF-L1006 (WT + pPL2i) (1006) and NF-L1008 (WT + L140Fi) (1008). (C) Quantitative comparison of PrfA protein levels from integrant strains NF-L1006 (WT + pPL2i) and NF-L1039 (WT + WTi) (1039). (D) Quantitative comparison of PrfA protein levels from EMS mutant strain NF-L879 (879), NF-L1003 ( prfA) (1003), and integrant strain NF-L1067 (L140F + L140Fi) (1067). The amounts of total proteins loaded in each lane in panels B, C, and D are indicated.
|
![]() View larger version (17K): [in a new window] |
FIG. 7. actA expression of PrfA mutant strains and corresponding control strains during growth in broth culture. Units of GUS activity were determined at the indicated time intervals as described in Materials and Methods and were normalized for bacterial culture OD595 (51) using 4-methylumbilliferyl-ß-D-glucuronide as the substrate. The data shown are from duplicate samples and are representative of at least three independent experiments, expressed as average ± standarderror. (A) Growth of WT and PrfA mutant strains in BHI broth at 37°C as measured by OD595 of cultures. (B) actA expression from strains NF-L476 (WT), NF-L1003 ( prfA), NF-L1006 (WT + pPL2i), NF-L1039 (WT + WTi), and NF-L1040 (WT + L147Pi). (C) actA expression from strains NF-L476 (WT), NF-L879 (EMS L140F), and NF-L1008 (WT + L140Fi). (D) actA expression from strains NF-L476 (WT), NF-L879 (EMS L140F), and NF-L1067 (L140F + L140Fi).
|
Construction of an L. monocytogenes strain containing two copies of L140Fi. To examine the potential effects on PrfA-dependent gene expression that would result from the presence of multiple copies of the PrfA L140F mutation, the L140Fi allele was introduced via integration into the EMS mutant NF-L879 to generate NF-L1067 (L140F + L140Fi). Unshaken overnight cultures of NF-L1067 were observed to settle to the bottoms of culture tubes (Fig. 1), although NF-L1067 had no obvious growth defects in broth culture (data not shown). Approximately two- to fourfold more PrfA protein was produced in NF-L1067 than in its EMS mutant parent strain, NF-L879 (Fig. 6D), but hly, actA, and plcB expression levels were not found to differ significantly between the two strains (Table 2 and Fig. 5 and 7D). These data indicate that the induction of PrfA-dependent gene expression was already saturated with the amount of activated PrfA protein synthesized from one L140Fi allele, and therefore, the introduction of a second copy resulted in no additional increase.
Intracellular growth and cell-to-cell spread of prfA mutant strains in tissue culture cells.
The capacity of L. monocytogenes to replicate within the cytosol and spread to adjacent cells can be assessed by visualizing zones of cell clearing (plaques) in monolayers of infected tissue culture cells (45). Strains that are deficient in intracellular growth and/or cell-to-cell spread fail to form plaques or form plaques of reduced size. It has been demonstrated that strains lacking functional PrfA do not escape from host cell vacuoles and are unable to replicate within cells or spread to adjacent cells; these strains do not form plaques in monolayers of mouse L2 fibroblasts (13, 30). As anticipated, strains NF-L1003 (
prfA), NF-L1009 (
prfA + pPL2i), and NF-L1042 (
prfA + L147Pi) failed to form plaques in monolayers of L2 fibroblasts (Table 2). The EMS mutant NF-L879 formed plaques that were
79% the size of those formed by WT NF-L476 (Table 2). In the presence of chloramphenicol, integrant strain NF-L1041 (
prfA + WTi) formed plaques smaller than those formed by NF-L476 (63.5% ± 6.4% [average ± standard deviation with NF-L476 set at 100%]); however, in the absence of the antibiotic, plaque formation was comparable to that of the WT (data not shown). Chloramphenicol therefore appeared to reduce the efficiency of plaque formation, despite the presence of the cat gene in the pPL2 integrant strains. The inclusion of chloramphenicol was necessary to ensure the stability of the integrated L140Fi allele; therefore, the drug was included for all pPL2 integrants, and the plaque size of NF-L1041 (
prfA + WTi) was set at 100% for comparison with mutant prfA integrant strains. The integrant strain NF-L1011 (
prfA + L140Fi) was still found to form reproducibly smaller plaques than strain NF-L1041 (
prfA + WTi); however, the plaques were only slightly (
10%) smaller than those formed in the presence of the WTi allele (Table 2). L. monocytogenes strains containing the L140Fi allele may therefore be slightly deficient in invasion, intracellular replication, and/or cell-to-cell spread. No significant differences were observed in plaque size or frequency for any of the various prfA integrant strains in the WT background or, interestingly, for NF-L1067 containing two copies of L140Fi (Table 2). Experiments examining bacterial infection of the macrophage-like cell line J774 indicated that all integrant strains had similar intracellular growth for at least 7 h postinfection (data not shown).
L. monocytogenes strains containing L140Fi exhibit decreased swimming motility.
Previous work has demonstrated that two strains of L. monocytogenes that contained constitutively activated forms of PrfA protein (PrfA E77K and PrfA G155S) exhibited decreased swimming motility in soft agar (43). We therefore examined the swimming motility of the PrfA L140F strains. The EMS mutant NF-L879 and integrants NF-L1008 (WT + L140Fi), NF-L1011 (
prfA + L140Fi), and NF-L1067 (L140F + L140Fi) were all strikingly deficient in swimming motility, while the other integrants were similar in motility to WT strain NF-L476 (Table 2). Strains containing constitutively activated forms of PrfA (such as PrfA L140F) may thus be deficient in nutrient acquisition and exhibit decreased fitness for survival in environments outside of host cells.
|
|
|---|
In contrast to the three previously described mutations within PrfA that lead to the protein's constitutive activation (PrfA G145S, PrfA G155S, and PrfA E77K), the PrfA L140F mutation conferred some degree of toxicity upon bacterial cells. Multiple attempts to reconstruct the PrfA L140F mutation in WT L. monocytogenes by allelic replacement proved unsuccessful. In addition, when the mutant allele was integrated into an ectopic location on the L. monocytogenes chromosome (as in strain NF-L1011 [
prfA + L140Fi]), the L140Fi allele could not be stably maintained in the absence of selective pressure (unlike the WT allele, which was stable without selection). The observation that unshaken overnight cultures of L. monocytogenes strains harboring the L140Fi allele settled to the bottoms of culture tubes suggests that the presence of PrfA L140F results in an altered bacterial surface structure or cell density (Fig. 1). Altered bacterial cell physiology or morphology probably reflects changes in the spectrum of gene products normally produced by the bacteria during growth in broth culture; these products are likely to be either directly or indirectly regulated by PrfA. Preliminary analysis of L. monocytogenes membranes and secreted proteins of PrfA L140F strains using denaturing PAGE indicates readily detectable changes in the abundance of several polypeptide species (K. K. Y. Wong, unpublished data). The PrfA-directed alterations in L. monocytogenes bacterial surfaces or cell physiology may function to promote bacterial survival in the cytosol of infected host cells, an environment demonstrated to induce PrfA activation (42). It is notable that, in contrast to the pPL2-prfA L140F reconstructed L. monocytogenes strains, the PrfA L140F mutation is stably maintained in the original NF-L879 mutant isolate; it is possible that this strain contains additional mutation(s) that alleviate the toxicity associated with this PrfA mutant allele. NF-L879, however, formed plaques in fibroblast monolayers that were significantly smaller than those formed by WT strains and smaller than those formed by the isogenic NF-L1011 (
prfA + L140Fi) mutant (79% ± 3% for NF-L879 versus 90% ± 2% for NF-L1011). It is possible, therefore, that the mutation in NF-L879 that compensates for the presence of the L140Fi allele adversely affects the ability of L. monocytogenes to spread to adjacent cells. Alternatively, NF-L879 may contain an independent mutation, unrelated to the presence of L140Fi, that reduces cell-to-cell spread. We do not believe that the L140Fi suppressor mutation is present in either NF-L1011 or NF-L1008, as these strains do not stably maintain the L140Fi allele in the absence of drug selection, and multiple L. monocytogenes isolates obtained from independent pPL2-prfA L140F vector transformations were indistinguishable from NF-L1011 and NF-L1008 in independent assays (K. K. Y. Wong, unpublished data). Additionally, L. monocytogenes integrants containing the pPL2-prfA L140F plasmid were isolated at the same frequency and with the same colony growth characteristics on agar plates as integrants containing the pPL2-prfA or pPL2 vector, a result that suggests that the toxicity associated with the presence of L140Fi is not severe.
The relative levels of PrfA protein have been shown to be important for optimal induction of virulence gene expression (5, 12, 13, 36). PrfA synthesis increases upon entry of L. monocytogenes into host cells (36), and this increase is necessary to direct the expression of gene products required for bacterial spread to adjacent cells (5, 12, 13). The data presented here indicate that saturating levels of virulence gene expression are more rapidly achieved by activated forms of PrfA. For example, the introduction of a second WT copy of prfA into L. monocytogenes doubled the production of LLO and ActA (Table 2 and Fig. 7). However, no significant increase in either actA or hly expression was observed for L. monocytogenes strains containing two L140Fi alleles (NF-L1067 [L140F + L140Fi]) versus those with one copy (NF-L879 and NF-L1011 [
prfA + L140Fi]) (Table 2 and Fig. 4 and 7), even though the presence of a second copy increased the levels of PrfA protein produced in these strains (Fig. 6). These results suggest that the expression of PrfA-dependent genes is most sensitive to variations in PrfA protein levels when PrfA is present in its nonactivated state.
The apparent phenotypic dominance of the L140Fi allele over the WT allele is interesting in light of predictions that PrfA is active as a multimer. These predictions are based upon the homology PrfA shows with Crp and upon the recently solved crystal structure of PrfA (37, 49; http://www.rcsb.org/pdb/). The merodiploid integrant NF-L1008 (WT + L140Fi) presumably produces both WT PrfA and PrfA L140F, but this has not been definitely demonstrated. The PrfA L140F protein would be predicted to activate expression not only from its own upstream plcA promoter but also from that of the WT copy, thus leading to high-level expression of both proteins. It is possible that PrfA L140F has sufficiently high promoter binding affinity to outcompete the WT protein at all promoters examined; it has been reported that WT PrfA could compete and neutralize the activation of virulence genes by an activated PrfA form (PrfA G145S) if the WT PrfA was produced in trans from a multicopy plasmid (37). We favor the possibility that PrfA L140F may induce conformational changes in the WT protein upon multimerization that lead to activation of both PrfA molecules. Alternatively, the PrfA L140F mutation may serve to stabilize the formation of active PrfA dimers.
As mentioned above, the crystal structure of PrfA has recently been solved and released (Protein Data Bank accession code 1OMI [http://www.rcsb.org/pdb/]). The structure obtained indicates that PrfA is structurally similar to the cAMP receptor protein (Crp) from E. coli (50). Figure 8 depicts the locations of the PrfA L140F and the PrfA L147P mutations within the WT structure. Also depicted is the original PrfA G145S mutation, the first mutation identified that resulted in a constitutively active form of PrfA (PrfA*) (37). The PrfA L140F and L147P mutations are located very close to the DNA-binding helix-turn-helix (HTH) domain of PrfA. The phenylalanine side chain of PrfA L140F, based on its location within the WT structure, might possibly alter the positioning of the HTH domain to facilitate the interaction of this region with DNA; confirmation of this hypothesis awaits further structural and functional analyses of PrfA L140F. In contrast, proline substitutions often introduce dramatic turns into protein chains, and thus, the PrfA L147P substitution might result in improper folding and protein degradation, consistent with the failure of this strain to produce detectable PrfA protein.
![]() View larger version (127K): [in a new window] |
FIG. 8. Locations of PrfA mutations in the crystal structure of PrfA (http://www.rcsb.org/pdb/). The two diagrams illustrate two different views of the PrfA dimer. The blue and yellow traces are the C traces of the two monomers of PrfA. The HTH motifs are shown in red. The previously described PrfA* mutation (G145S) is included for comparison (37).
|
This work was supported by Public Health Service grant AI41816 (N.E.F.) from the National Institutes of Health and by the M. J. Murdock Charitable Trust.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»